Poulomi Sengupta, Sudipta Basu and Shiladitya Sengupta Pages 254 - 260 ( 7 )
Understanding the mechanisms underlying different cellular signaling pathways implicated in the pathogenesis of cancer are leading to the identification of novel drug targets as well as novel drug candidates. Multiple targeted therapeutics that modulate aberrant molecular pathways have already reached the clinic. However, targeted therapeutics can exert mechanism-driven side effects as a result of the implication of the molecular target in normal physiological functions besides tumorigenesis. We hypothesize that targeted therapeutics can be optimized by merging them with nanotechnology, which offers the potential for preferential targeting to the tumor, resulting in increased intratumoral concentrations of the active agent with reduced distribution to other parts of the body. This review will address some of the emerging concepts that integrate these two disciplines to engineer novel nanovectors that target different signaling pathways.
Nanotechnology, drug delivery, signaling pathways, nanoparticles, cancer, RECEPTOR KINASES, Downstream Signaling, ONCOGENIC SIGNALING, EGFR-overexpressing cancer
Harvard-MIT Division of Health Science and Technology, 65 Landsdowne Street, Partners Research Building, Room 325, Cambridge, MA 02139, USA.